CSBR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q4

FY2027Q1

16.61M

-2.5%

0.090

-72.73%

12.89M

+4.3%

-0.050

-59.62%

15.05M

+7.5%

-0.010

-150%

Estimates Revision

The market is revising No Change the revenue expectations for Champions Oncology, Inc. (CSBR) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 3.67%.

Revenue Estimates for FY2026

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2026

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+3.67%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast CSBR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSBR is USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

12.00

Averages

High

12.00

Current: 0.000

Low

12.00

Averages

High

12.00

Craig-Hallum

Matt Hewitt

Strong Buy

Maintains

$8 → $12

2025-03-12

Reason

Craig-Hallum

Matt Hewitt

Price Target

$8 → $12

2025-03-12

Maintains

Strong Buy

Reason

Craig-Hallum analyst Matt Hewitt raised the firm's price target on Champions Oncology to $12 from $8 and keeps a Buy rating on the shares. The firm notes the company reported strong Q3 results, which featured a substantial data licensing deal signed by a large pharma company for rights to their cancer data. The company recognized $4.5M for this with potential of up to $8M. This deal led to revenues of $17M vs. $12.9M estimates and led to beats across the board. Craig-Hallum sees this company capitalizing on its large data offerings as it seeks to make drug development more efficient for customers.

Valuation Metrics

The current forward P/E ratio for Champions Oncology Inc (CSBR.O) is 133.20, compared to its 5-year average forward P/E of 42.09. For a more detailed relative valuation and DCF analysis to assess Champions Oncology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

42.09

Current PE

133.20

Overvalued PE

92.05

Undervalued PE

-7.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

21.86

Current EV/EBITDA

128.51

Overvalued EV/EBITDA

73.06

Undervalued EV/EBITDA

-29.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.82

Current PS

1.52

Overvalued PS

2.48

Undervalued PS

1.15

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CSBR News & Events

Events Timeline

No data

News

2.0

01-07NASDAQ.COM

Champions Oncology (CSBR) Earnings Transcript

3.0

2025-12-15Benzinga

Key Stocks Reporting Earnings This Week: Micron, FuelCell, Carnival, and Others

9.5

2025-09-15Newsfilter

Transcript of Champions Oncology, Inc. (CSBR) Earnings Call for Q1 2026

People Also Watch

Frequently Asked Questions

What is Champions Oncology Inc (CSBR) stock price today?

The current price of CSBR is 6.78 USD — it has decreased -0.16 % in the last trading day.

What is Champions Oncology Inc (CSBR)'s business?

Champions Oncology, Inc. is a preclinical and clinical research services provider. The Company is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs through its translational oncology solutions (TOS). This technology ranges from computational-based discovery platforms, oncology software solutions, and proprietary experimental tools such as in vivo, ex vivo and biomarker platforms. Utilizing its TumorGraft Technology Platform (the Platform), it provides select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. It also sells Lumin Bioinformatics (Lumin), an oncology data-driven software program which contains comprehensive information derived from its research services and clinical studies. Lumin leverages a large data center coupled with analytics and artificial intelligence to provide a robust tool for computational cancer research.

What is the price predicton of CSBR Stock?

Wall Street analysts forecast CSBR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CSBR is USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Champions Oncology Inc (CSBR)'s revenue for the last quarter?

Champions Oncology Inc revenue for the last quarter amounts to 15.04M USD, increased 11.46 % YoY.

What is Champions Oncology Inc (CSBR)'s earnings per share (EPS) for the last quarter?

Champions Oncology Inc. EPS for the last quarter amounts to 0.02 USD, decreased -60.00 % YoY.

What changes have occurred in the market's expectations for Champions Oncology Inc (CSBR)'s fundamentals?

How many employees does Champions Oncology Inc (CSBR). have?

Champions Oncology Inc (CSBR) has 213 emplpoyees as of January 10 2026.

What is Champions Oncology Inc (CSBR) market cap?

Today CSBR has the market capitalization of 94.15M USD.